Skip to main content
Download PDF

Interstitial pneumonitis during rituximab-containing chemotherapy for primary central nervous system lymphomas: a case report and review of literature

Chinese Neurosurgical Journal volume 4, Article number: 1 (2018) Cite this article

Abstract

Background

Primary central nervous system lymphoma(PCNSL) is a rare kind of non-Hodgkin lymphoma. Rituximab combined with high-dose methotrexate, cytarabine and dexamethasone (R-MAD regimen) were reported effective for PCNSL patients. Rituximab can cause several side effects, including fever, chills and rigors.

Case presentation

In this case report, we demonstrate rituximab-induced interstitial pneumonitis in a PCNSL patient who has been treated with R-MAD regimen. The patient recovered after treatment and she remains complete remission after following consolidation chemotherapy.

Conclusions

Here is no report of potential fatal complications of Rituximab like interstitial pneumonitis nowadays in PCNSL patients. As Rituximab is widely used, physicians should raise their awareness of this rare complication and detect RTX-ILD in early stage.

Background

Primary central nervous system lymphoma(PCNSL)are extranodal Non-Hodgkin lymphomas confined to the brain, eyes, leptomeninges, or spinal cord in the absence of systemic lymphoma,and is predominantly (90–95%) of the diffuse large B-cell lymphoma (DLBCL) subtype [1]. Methotrexate containing regiment(high-dose methotrexate(MTX) with cytarabine(Ara-C) and dexamethasone) is presently considered as the first choice for PCNSL patients whose preparing to take chemotherapy. Rituximab(RTX) is a chimeric anti-CD20 monoclonal antibody. It is reported that the complete response rate and overall survival in PCNSL accessed to high-dose methotrexate-contained regiment can be improved with the addition of Rituximab [2]. We previously retrospective analyzed 35 PCNSL patients in hematology department of Beijing Tiantan hospital who received R-MAD regimen and prove its safety and effectiveness [3]. During the infusion of RTX, there can be some common side effect including fever, chills, and rigors. Severe respiratory conditions have never been reported in PCNSL patient before. To raise awareness of this serious complication of RTX containing treatment, we demonstrate rituximab-induced interstitial pneumonitis in a PCNSL patient who has been treated with R-MAD(Rituximab, high-dose methotrexate, cytarabine, and dexamethasone) regimen.

Case description

Four months ago, a 33y female patient complained low fever with acratia, night sweating, and disorder of left limb’s activity. Her brain CT showed right lateral ventricle occupying lesion. Postoperative pathology showed diffuse large B-cell lymphoma, after which she received 5 cycles of R-MAD regimen (Rituximab 600 mg d1, high-dose methotrexate, cytarabine, and dexamethasone) chemotherapy (Fig. 1). Then her left limbs activity fully recovered.

Fig. 1
figure1

a, b MRI enhancement revealed: on the right side of the thalamus a block of long T2 long T1 signal can be seen,the boundary is clear, the range is 44 × 40 × 34 mm. Enhanced scanning showed inhomogeneous enhancement. Massive edema can be seen around the lesion. The third ventricle was compressed,bilateral ventricles dilated. Midline shift left slightly. c, d MRI enhancement after surgery and 5 cycles of R-MAD chemotherapy showed: right side of the occipital skull and soft tissue post operation change. The right lateral ventricles triangle and the temporal angle were irregular enlarged, the ventricular wall was less structured

Full size image

Two weeks after the fifth cycle of R-MAD regimen chemotherapy (Rituximab 600 mg d1, high-dose methotrexate, cytarabine, and dexamethasone), she was admitted to hospital with the symptoms of fever and abdominal pain. The physical examination revealed temperature 38.7 °C; pulse 82/min; respiration 20 times/min; blood pressure 120/80 mmHg; Clear consciousness; mild anemic appearance; no swelling of superficial lymphnode. Her chest was clear to percussion and auscultation, and her heart and abdomen showed no abnormality, also, her lower limbs has no swelling. Blood routine: white cell count(WBC) 4.68*109/L, percentage of neutrophilic granulocyte 75.9%, hemoglobin 119 g/l, platelet count 55*109/L. Stool routine: red blood cell (− /HPF), white blood cell count(− /HPF), occult blood(−), fungi(− /HPF).

Preliminary diagnosis was a gastroenteritis caused by unhygienic food. Cefmetazole were prescribed for her. After using cefmetazole for 1 day, her temperature raised up to 40 °C.Blood routine: white blood cell count 2.08*109/L, neutrophilic granulocyte 1.26*109/L, hemoglobin 101 g/l, platelet count 80*109/L. C-reactive protein 20.05 mg/L. Procalcitonin <0.05 ng/ml. X-ray examination showed intensification of pulmonary grains, bilateral exudative change, suggesting pulmonary infection. So, meropenem was given. Though the patient complained no cough, no expectoration or dyspnea, she had cyanosis and bilateral coarse breath sounds on pulmonary auscultation. Blood gas demonstrated type I respiratory failure (pH 7.44, PaO241mmHg, PaCO234 mmHg, SaO2 78%). Chest CT demonstrated bilateral lung fields with diffuse ground glass opacities, compatible with interstitial pneumonitis (Fig. 2).

Fig. 2
figure2

a, b Helical computed tomographic scanning showing bilateral diffuse ground glass opacities, partialpleura thickening, crescent shaped liquid density of bilateral chest wall. c, d A repeat CT scan 7 days after glucocorticoid and antibiotic therapy showing almost complete resolution of the interstitial infiltration

Full size image

Blood routine, procalcitonin, c-reactive protein retesting results suggested severe infectious pneumonia. If the infection of pulmonary was the only existing pathogenesis, the patient should have responded to antibiotics treatment, but turned out not. Thus, rituximab induced lung disease (RTX-ILD) was considered possible. After that high-dose intravenous steroid (80 mg urbason) was given immediately with continuous meropenem treatment. One day after intravenous steroid, her temperature back to normal. Arterial blood gas changes see in Table 1. CT reexamination revealed significant lesion absorption, and normal pulmonary grain after seven-day steroid treatment (Fig. 2). In addition, her chest was clear to percussion and auscultation, and her saturation of blood oxygen was at normal level. After that, the patient received two cycles of pemetrexed and two cycles of EA regimen (Etoposide and cytarabine) as consolidation chemotherapy. There were no signs of recurrence of lymphoma on the following MRI and PET scan of the patient.

Table 1 Change of arterial blood gas
Full size table

Discussion

Rituximab(RTX) has been proved effectively in treating malignant and autoimmune disease including: lymphoma, leukemia, rheumatoid arthritis, Wegeners granulomatosis [4], and benefit non-Hodgkin’s lymphoma (NHL) and RA patients [5, 6]. Infusion-related symptom complex have been observed during the use of RTX which consists fever, chills and rigors. During clinical trials, 9-15% of the patients showed symptoms of infusion-related reactions, while 30% of patients had respiratory manifestations (cough, bronchospasm, sinusitis and rhinitis). These complications are generally mild and self-limited. Severe side effects such as anaphylactic shock and acute respiratory distress syndrome were rare, fatal in 0.04-0.07%. Interstitial lung disease is one of those potentially fatal complications of RTX therapy, it is reported that the overall incidence of RTX-ILD is less than 0.03% in phase III trials [7]. However, it is reviewed that in post-marketing literature the incidence is much higher, ranging from 3.7 -10% [4].The variance between these two incidences might due to different in target population. Phase III trials shown that RTX-ILD is of more severity in lymphoma than in rheumatological disorders, which may due to the difference of dosage used in treatment [8]. As for hematological disorders, the mean dosage of RTX was 7785 mg comparing to 2000 mg in rheumatological disorders. RTX is widely used for patients with B cell lymphoma and the majority case reports are from non-Hodgkin lymphoma patients. According to the previous research of our department, we found that with the use of RTX, the probability of complete response and overall survival in newly diagnosed PCNSL patients had been improved [1]. And this is the first time that R-ILD has been discovered in PCNSL patients.

The pathogenesis of R-ILD remains unclear. One hypothesis is pathogenic cytokine release. Tumor necrosis factor-α(TNF-α) and interleukins are thought to be the dominating contributing cytokines [9, 10]. Recently there was case reported that Nod-like receptor pyrin domain-containing protein 3(NLRP3)may act as an initiator of inflammation process in lung of R-ILD patient. The discovery of NLRP3 and related further researches could open a new sight into the pathologic mechanism and provide a new target for the treatment of RTX-ILD [11].

Rituximab induced lung disease have higher incidence in male and patient of their fifty to sixty. Mostly occurring 2 weeks after the latest cycle of infusion, the fourth cycle of RTX [12], average dose accumulated to 1500 mg/m2. Common complains of RTX-ILD included: dyspnea and cough. Other symptoms like fatigue, rigours, wheeze, hemoptysis, skin rash have also been reported. About 20.7% of the cases is detected radiologically without symptoms. Physical examinations may be unremarkable or without diffuse fine inspiratory crackles. As for typical radiological abnormalities, chest radio graph displaying diffuse bilateral lung infiltrates. In high-resolution or helical thoracic CT, ground-glass opacification(GGO), alveolitis, pulmonary fibrosis, alveolar hemorrhage, pleural effusions and consolidation can also be seen. PET-CT could indicate the activation of neutrophil within the lungs by showing 18-FDG accumulation in hypermetabolic lung nodules. Lung biopsy is not usually performed in RTX-ILD, in our case, the diagnosis was made on clinical and radiological basis. Her respiratory symptoms relieved greatly after steroid treatment thus we didn’t see the further need for invasive investigation. Anyway, pulmonary inflammation is a common feature in reported cases. A recent systematic review of the available studies showed various histological patterns including: organizing pneumonia, interstitial pneumonitis, desquamative interstitial pneumonia, diffuse alveolar damage, and usual interstitial pneumonia [13].

According to Wagner’s review, hypoxemia and saturation of blood oxygen decreasing is uniformly abnormal in RTX-ILD [14]. There’s also research signify fever was the most common presenting symptom [15].

In our case report, the patient was free of respiratory symptoms and no abnormal objective sign in lung except for cyanosis is a crucial clue, suggesting hypoxemia. Following arterial blood gas testing confirmed type I respiratory failure. Pulmonary function tests reveal restrictive pattern on spirometry and significant reduction in carbon monoxide diffusion capacity. Further test could be done to confirm diagnosis and evaluate the efficacy of treatment, like transbronchial lung biopsy, bronchoalveolarlavage. Blood culture, sputum culture, antineutrophil cytoplasmic antibody, procalcitonin, antibodies and DNA testing for acute virus and empirical treatment with antibiotics should be down to rule out bacterial infection.

Once RTX-ILD was considered, RTX treatment should be stopped immediately and provide intravenous steroid. Supporting treatment include oxygen-inspiration and noninvasive mechanical ventilation can be provided contingent on blood oxygen. RTX-ILD patients who do not respond to glucocorticoids is potential fatal. In a 21-day treatment, 5 mg of dexamethasone or 40 mg of methyl-prednisolone were used in the first three consecutive days, followed by prednisone taken orally with slow taper.14 Treatment for such severe RTX-ILD is still challenging. Some authors have suggested anti-TNFα therapy in severe cases. The first TNF-α antagonist and cytokine profiling treating was published by Yong-Kang Wu, but the he did not obtain an ideal outcome. Moreover, some clinical trials even indicated that TNF-α antagonists themselves may lead to a worse prognosis [16].

The retreatment of rituximab may probably deteriorate pulmonary condition among the patients who had experience R-ILD [17, 18]. However some other reports presented opposite result. Those patients who has been retaken Rituximab contained regimens showed uneventful outcome [19]. Therefore, the decision should be made carefully. As the probability of curing the disease may be improved while the incident rate of potential pulmonary toxicity may be improved as well [14].

Conclusion

Rituximab is widely used in non-Hodgkin lymphomas including PCNSL. Rituximab induced lung disease is a rare yet potential fatal complication. Early diagnosis and treatment including intravenous glucocorticoids, oxygen-inspirationare are of great importance. To detect RTX-ILD in early stage, physicians subscribing RTX should be clearly aware of its common and rare complications, once patients applying RTX appear cyanosis or hypoxemia, futher examinations including arterial blood gas test and chest CT should be done as soon as possible. The pathogenesis of RTX-ILD remains unclear, NLRP3 may provide a new target for treatment in the future.

Abbreviations

Ara-C:

Cytarabine

CNS:

Central nervous system

EA:

Etoposide and cytarabine

GGO:

Ground-glass opacification

HPF:

High power field

MTX:

Methotrexate

NHL:

Non-Hodgkin’s lymphoma

NLRP3:

Nod-like receptor pyrin domain-containing protein 3

PaCO2:

Partial pressure of carbon dioxide of artery

PaO2:

Partial pressure of oxygen of artery

PCNSL:

Primary central nervous system lymphoma

RA:

Rheumatoid arthritis

R-MAD regimen:

Rituximab,high-dose methotrexate, cytarabine and dexamethasone

RTX:

Rituximab

RTX-ILD:

Rituximab induced lung disease

SaO2:

Arterial oxygen saturation

TNF-α:

Tumor necrosis factor-α

WBC:

White blood cells

References

  1. 1.

    Wang CC, Carnevale J, Rubenstein JL. Progress in central nervous system lymphomas[J]. Br J Haematol. 2014;166:311–25.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plushigh-dose methotrexate versus high-dose methotrexate alone inpatients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009;374:1512–20.

    CAS  Article  PubMed  Google Scholar 

  3. 3.

    Xuefei S, Jin L, Shengju S, et al. Efficacy of rituximab combined with chemotherapy regimen for the treatment of primary centralnervous system lymphomas. Chin J Neurosurg. 2016;32:388–92.

    Google Scholar 

  4. 4.

    Montero AJ, McCarthy JJ, Chen G, Rice L. Acute respiratory distress syndrome after rituximab infusion. Int J Hematol. 2005;82:324–6.

  5. 5.

    Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–42.

    CAS  Article  PubMed  Google Scholar 

  6. 6.

    Czuczman MS, Gregory SA. The future of CD20 monoclonal antibody therapy in B-cell malignancies. Leuk Lymphoma. 2010;51(6):983–94.

    CAS  Article  PubMed  Google Scholar 

  7. 7.

    Liu X, Hong XN, Gu YJ, Wang BY, Luo ZG, Cao J. Interstitialpneumonitis during rituximab-containing chemotherapy fornon-Hodgkin lymphoma. Leuk Lymphoma. 2008;49(9):1778–83.

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    Shaw T, Quan J, Totoritis MC. B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience. Ann Rheum Dis. 2003;62(Suppl. 2):ii55–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. 9.

    Schmidt K, Martinez-Gamboa L, Meier S, et al. Bronchoalveoloar lavage fluid cytokinesand chemokines as markers and predictorsfor the outcome of interstitial lungdisease in systemic sclerosis patients. ArthritisRes Ther. 2009;11:R111.

    Article  Google Scholar 

  10. 10.

    Vasakova M, Sterclova M, Kolesar L, et al. Bronchoalveolar lavage fluid cellular characteristics,functional parameters and cytokine and chemokine levels in interstitial lung diseases. Scand J Immunol. 2009;69:268–74.

    CAS  Article  PubMed  Google Scholar 

  11. 11.

    Kong H, Wang Y, Zeng X, Zhu Q, Xie W, Dai S. Involvement of NLRP3 inflammasome in rituximab-induced interstitial lung disease: a case report. J Clin Pharm Ther. 2014;39(6):691–4.

    CAS  Article  PubMed  Google Scholar 

  12. 12.

    Lioté H, Lioté F, Séroussi B, et al. Rituximab-induced lung disease: a systematic literature review. Eur Respir J. 2010;35:681–7.

    Article  PubMed  Google Scholar 

  13. 13.

    Hadjinicolaou AV, Nisar MK, Parfery H, Chilvers ER, Ostör AJ. Non-infectious pulmonary toxicity of rituximab: a systematic review. Rheumatology (Oxford). 2012;51(4):653–62.

    CAS  Article  Google Scholar 

  14. 14.

    Wagner SA, Mehta AC, Laber DA. Rituximab-induced interstitial lung disease. Am J Hematol. 2007;82:916–9.

    CAS  Article  PubMed  Google Scholar 

  15. 15.

    Liu X, Hong X-N, Ya-Jia G, Wang B-Y, Luo Z-G, Cao J-N. Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma. Leuk Lymphoma. 2008;49(9):1778–83.

    CAS  Article  PubMed  Google Scholar 

  16. 16.

    Tan J. Ni X.TNF-α antagonist may not be suitable for severe rituximab-induced interstitial lung disease. J Clin Pharm Ther. 2015;40(3):249–50.

    CAS  Article  PubMed  Google Scholar 

  17. 17.

    Alexandrescu DT, Dutcher JP, O’Boyle K, Albulak M, OisethS WPH. Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin lymphoma. Leuk Lymphoma. 2004;45:2321–5.

    Article  PubMed  Google Scholar 

  18. 18.

    Kanelli S, Ansell SM, Habermann TM, Inwards DJ, Tuinstra N, Witzig TE. Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis. Leuk Lymphoma. 2001;42:1329–37.

    CAS  Article  PubMed  Google Scholar 

  19. 19.

    Byrd JC, Peterson BL, Morrison VA, Park K, Jacobson R, Hoke E, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from cancer and leukemia group B 9712 (CALGB 9712). Blood. 2003;101:6–14.

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by department of hematology, Beijing Tiantan Hospital, Capital Medical University.

Funding

National Natural Science Foundation of China (81272842) and Beijing Natural Science Foundation of China (7172071).

Availability of data and materials

The data sets used during the current study are available from the corresponding author on reasonable request.

Author information

Affiliations

  1. Department of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100050, China

    Yuchen Wu, Xuefei Sun, Jing Liu, Jun Qian, Xueyan Bai, Yuedan Chen & Yuanbo Liu

Authors
  1. Yuchen Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xuefei Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jing Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jun Qian
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xueyan Bai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yuedan Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yuanbo Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

XS, XB and YC participated in diagnosis and therapeutic process of the patient, YW was a major contributor in writing the manuscript, JL provided language instruction. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Yuanbo Liu.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

The clinical details and images was obtained from the patient with written informed consent for publication.

Competing interests

The authors declare that they have no competing interests.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wu, Y., Sun, X., Liu, J. et al. Interstitial pneumonitis during rituximab-containing chemotherapy for primary central nervous system lymphomas: a case report and review of literature. Chin Neurosurg Jl 4, 1 (2018). https://doi.org/10.1186/s41016-017-0106-3

Download citation

Keywords

  • Central nervous system neoplasm
  • Lymphoma
  • Interstitial pneumonitis
  • Rituximab
  • R-MAD regimen
  • Rituximab induced lung disease
  • Chemotherapy
  • Immunotherapy

Chinese Neurosurgical Journal

ISSN: 2057-4967

Contact us